Researchers found that a new drug called ALXN1840 (tiomolibdate choline) shows promise in treating Wilson disease, a rare genetic condition that causes copper to accumulate in the body, leading to serious health issues. In a recent Phase 2 trial, patients taking ALXN1840 experienced a significant improvement in their copper balance, which is crucial for preventing damage to organs like the liver and brain.

This discovery is particularly relevant for people with Wilson disease, who often struggle with the effects of copper buildup despite long-term treatment with existing therapies. The trial involved nine patients and demonstrated a notable reduction in daily copper balance, with a mean decrease of 6.08 mg over 21 days. This means that ALXN1840 effectively helps the body eliminate excess copper, potentially leading to better overall health and reduced risk of complications associated with the disease.

The study is an early-stage Phase 2 trial, which means while the results are promising, further research is needed to confirm the drug’s effectiveness in larger populations. The participants had been on standard treatment for an average of 16 years, highlighting the potential of ALXN1840 to mobilize and eliminate copper that previous therapies could not. The findings suggest that this new treatment could offer a meaningful option for those living with Wilson disease.

For those interested in copper-related health issues, it may be worth discussing the latest findings with a healthcare provider, especially if they or someone they know is affected by Wilson disease. Staying informed about new treatments can help in making better health decisions.

Source: globenewswire.com